How a hugely overpriced hepatitis drug helped drive up U.S. health spending

There's one especially eye-catching number in a new report by Medicare actuaries  about U.S. healthcare spending: 12.6%. The actuaries have no doubt what's driving the increase. It's "a result of expensive new treatments for hepatitis C," mainly Gilead Science's Sovaldi, which cost about $84,000 for a 12-week treatment, or about $1,000 per once-a-day pill.
Read more: http://ift.tt/1HXJnqV